CN116801882A - 杂环化合物治疗与激酶耐药突变相关的疾病的用途和方法 - Google Patents

杂环化合物治疗与激酶耐药突变相关的疾病的用途和方法 Download PDF

Info

Publication number
CN116801882A
CN116801882A CN202280011390.5A CN202280011390A CN116801882A CN 116801882 A CN116801882 A CN 116801882A CN 202280011390 A CN202280011390 A CN 202280011390A CN 116801882 A CN116801882 A CN 116801882A
Authority
CN
China
Prior art keywords
compound
group
ret
alkyl
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280011390.5A
Other languages
English (en)
Chinese (zh)
Inventor
陈忠辉
袁晓曦
雷冬梅
韩润丰
韩晓军
田强
宋宏梅
王晶翼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Original Assignee
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Kelun Biotech Biopharmaceutical Co Ltd filed Critical Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Publication of CN116801882A publication Critical patent/CN116801882A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280011390.5A 2021-03-24 2022-03-21 杂环化合物治疗与激酶耐药突变相关的疾病的用途和方法 Pending CN116801882A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN202110316525 2021-03-24
CN2021103165256 2021-03-24
CN2022101097668 2022-01-28
CN2022074619 2022-01-28
CN202210109766 2022-01-28
CNPCT/CN2022/074619 2022-01-28
PCT/CN2022/081890 WO2022199503A1 (zh) 2021-03-24 2022-03-21 杂环化合物治疗与激酶耐药突变相关的疾病的用途和方法

Publications (1)

Publication Number Publication Date
CN116801882A true CN116801882A (zh) 2023-09-22

Family

ID=83396096

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280011390.5A Pending CN116801882A (zh) 2021-03-24 2022-03-21 杂环化合物治疗与激酶耐药突变相关的疾病的用途和方法

Country Status (7)

Country Link
US (1) US20250268897A1 (https=)
EP (1) EP4316490A4 (https=)
JP (1) JP2024511389A (https=)
KR (1) KR20230159367A (https=)
CN (1) CN116801882A (https=)
AU (1) AU2022242476A1 (https=)
WO (1) WO2022199503A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022022398A1 (zh) * 2020-07-28 2022-02-03 四川科伦博泰生物医药股份有限公司 一种嘧啶类化合物的盐和晶型及其制备方法
CN120897743A (zh) 2023-05-19 2025-11-04 四川科伦博泰生物医药股份有限公司 杂环化合物治疗与ret基因改变相关疾病的用途和方法
WO2026017002A1 (zh) * 2024-07-16 2026-01-22 四川科伦博泰生物医药股份有限公司 以杂环化合物为活性成分的药物组合物、其制备方法及用途
GB202410599D0 (en) 2024-07-19 2024-09-04 Ellipses Pharma Ltd Therapeutics useful synergistic combinations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9145391B2 (en) * 2011-05-10 2015-09-29 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as Syk inhibitors
US10227329B2 (en) * 2016-07-22 2019-03-12 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
TWI791053B (zh) * 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
JP7060694B2 (ja) * 2018-01-18 2022-04-26 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての置換ピロロ［２，３－ｄ］ピリミジン化合物
JP7615056B2 (ja) 2019-02-19 2025-01-16 スーチュアン・コールン－バイオテック・バイオファーマシューティカル・カンパニー・リミテッド 複素環化合物、これを含む薬物組成物、その製造方法および使用
EA202193049A1 (ru) * 2019-05-21 2022-02-14 Вороной Инк. N-содержащее производное гетероарила и фармацевтическая композиция, содержащая его в качестве активного ингредиента для предупреждения или лечения рака
JP7732668B2 (ja) * 2019-08-05 2025-09-02 北京志健金瑞生物医▲薬▼科技有限公司 窒素含有多環式縮合環系化合物、その薬学的組成物、製造方法及び用途

Also Published As

Publication number Publication date
US20250268897A1 (en) 2025-08-28
EP4316490A4 (en) 2025-03-05
EP4316490A1 (en) 2024-02-07
KR20230159367A (ko) 2023-11-21
WO2022199503A1 (zh) 2022-09-29
JP2024511389A (ja) 2024-03-13
AU2022242476A1 (en) 2023-10-26

Similar Documents

Publication Publication Date Title
WO2021043077A1 (zh) 一种取代吡嗪化合物、其制备方法和用途
CN116801882A (zh) 杂环化合物治疗与激酶耐药突变相关的疾病的用途和方法
JP6200520B2 (ja) 置換２−アミノピリジンプロテインキナーゼ阻害剤
CN113316578B (zh) 杂环化合物、包含其的药物组合物及其制备方法和用途
CN118055933B (zh) 选择性parp1抑制剂及其应用
US20160280719A1 (en) Pyrrolopyrrolone derivatives and their use as bet inhibitors
JP2024505732A (ja) ピリドピリミジノン系誘導体及びその製造方法と使用
CN112574201B (zh) 芳基胺类化合物、包含其的药物组合物及其制备方法和用途
CN120897743A (zh) 杂环化合物治疗与ret基因改变相关疾病的用途和方法
CN119301101A (zh) 甲基吡唑化合物、包含其的药物组合物及其制备方法和用途
CA3130478A1 (en) Heteroaryl derivatives, and pharmaceutical composition comprising the same as active ingredient
RU2828045C2 (ru) Гетероциклическое соединение, фармацевтическая композиция, содержащая его, способ его получения и его применение
CA3210109A1 (en) Use of heterocyclic compound in treating diseases related to kinase drug-resistant mutation and method therefor
CN116761801A (zh) 具有蛋白激酶抑制活性的杂环化合物、包含其的药物组合物及其制备方法和用途
EP4556478A1 (en) Tgf-beta inhibitor compound and use thereof
CN117126140A (zh) 具有蛋白激酶抑制活性的杂环化合物、包含其的药物组合物及其制备方法和用途
CN116903626A (zh) 芳基酰胺化合物、包含其的药物组合物及其制备方法和用途
AU2024323272A1 (en) Jak inhibitor compound and use thereof
CN118434736A (zh) 含有肼基的化合物
HK40051009A (en) Heterocyclic compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof
HK1207862B (en) 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination